https://www.pharma-iq.com/rss/news en Mon, 27 Apr 2026 04:44:14 +0000 https://www.pharma-iq.com/pre-clinical-discovery-and-development/news/msd-announces-phase-iii-data-on-investigational-treatment-to-lower-ldl-cholesterol-ldl-c?utm_medium=RSS https://www.pharma-iq.com/pre-clinical-discovery-and-development/news/msd-announces-phase-iii-data-on-investigational-treatment-to-lower-ldl-cholesterol-ldl-c?utm_medium=RSS Mon, 17 Nov 2025 15:58:03 +0000 https://www.pharma-iq.com/pre-clinical-discovery-and-development/news/respiratory-syncytial-virus-and-the-race-for-a-vaccine?utm_medium=RSS https://www.pharma-iq.com/pre-clinical-discovery-and-development/news/respiratory-syncytial-virus-and-the-race-for-a-vaccine?utm_medium=RSS Tue, 29 Aug 2023 15:19:34 +0000 https://www.pharma-iq.com/business-development/news/big-pharma-ceos-announce-net-zero-action-plan?utm_medium=RSS https://www.pharma-iq.com/business-development/news/big-pharma-ceos-announce-net-zero-action-plan?utm_medium=RSS Tue, 29 Aug 2023 15:18:12 +0000 https://www.pharma-iq.com/clinical/news/uganda-declares-lockdown-and-merck-to-donate-vaccine-to-tackle-ebola?utm_medium=RSS https://www.pharma-iq.com/clinical/news/uganda-declares-lockdown-and-merck-to-donate-vaccine-to-tackle-ebola?utm_medium=RSS Tue, 29 Aug 2023 15:19:34 +0000 https://www.pharma-iq.com/pre-clinical-discovery-and-development/news/ukraines-clinical-trials-still-recruiting-despite-ongoing-war?utm_medium=RSS https://www.pharma-iq.com/pre-clinical-discovery-and-development/news/ukraines-clinical-trials-still-recruiting-despite-ongoing-war?utm_medium=RSS Tue, 29 Aug 2023 15:19:34 +0000 https://www.pharma-iq.com/business-development/news/the-impact-of-the-energy-crisis-on-pharma?utm_medium=RSS https://www.pharma-iq.com/business-development/news/the-impact-of-the-energy-crisis-on-pharma?utm_medium=RSS Tue, 29 Aug 2023 15:18:12 +0000 https://www.pharma-iq.com/business-development/news/trust-in-pharma-has-grown-since-the-pandemic-survey-finds?utm_medium=RSS https://www.pharma-iq.com/business-development/news/trust-in-pharma-has-grown-since-the-pandemic-survey-finds?utm_medium=RSS Tue, 29 Aug 2023 15:18:12 +0000 https://www.pharma-iq.com/pre-clinical-discovery-and-development/news/astrazeneca-shares-positive-results-for-its-drug-to-lower-cholesterol?utm_medium=RSS https://www.pharma-iq.com/pre-clinical-discovery-and-development/news/astrazeneca-shares-positive-results-for-its-drug-to-lower-cholesterol?utm_medium=RSS Tue, 29 Aug 2023 15:20:22 +0000 https://www.pharma-iq.com/manufacturing/news/into-initiative-aims-to-address-challenges-of-dpi-formulation?utm_medium=RSS https://www.pharma-iq.com/manufacturing/news/into-initiative-aims-to-address-challenges-of-dpi-formulation?utm_medium=RSS Tue, 29 Aug 2023 15:20:57 +0000 https://www.pharma-iq.com/clinical/news/keeping-tabs-on-pharma-landmark-new-drug-approvals-and-sanofis-push-for-diversity?utm_medium=RSS https://www.pharma-iq.com/clinical/news/keeping-tabs-on-pharma-landmark-new-drug-approvals-and-sanofis-push-for-diversity?utm_medium=RSS Tue, 29 Aug 2023 15:20:57 +0000 https://www.pharma-iq.com/pre-clinical-discovery-and-development/news/sanofi-announces-partnership-to-develop-new-class-of-oncology-therapeutics?utm_medium=RSS https://www.pharma-iq.com/pre-clinical-discovery-and-development/news/sanofi-announces-partnership-to-develop-new-class-of-oncology-therapeutics?utm_medium=RSS Tue, 29 Aug 2023 15:20:22 +0000 https://www.pharma-iq.com/pre-clinical-discovery-and-development/news/keeping-tabs-on-pharma-first-precision-medicine-for-autism-spectrum-disorders-shows-promise?utm_medium=RSS https://www.pharma-iq.com/pre-clinical-discovery-and-development/news/keeping-tabs-on-pharma-first-precision-medicine-for-autism-spectrum-disorders-shows-promise?utm_medium=RSS Tue, 29 Aug 2023 15:20:22 +0000